No Data
Revenues Not Telling The Story For Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) After Shares Rise 26%
Beyond Lackluster Earnings: Potential Concerns For Zhejiang Tailin BioEngineeringLtd's (SZSE:300813) Shareholders
Tailin Biotech: Report for the third quarter of 2024
Tailin (300813.SZ): The net income in the first three quarters decreased by 46.91% year-on-year to 11.3147 million yuan.
On October 29, Gleam Health reported on Tailin (300813.SZ) in the third quarter of 2024. The company achieved revenue of 0.242 billion yuan in the first three quarters, a year-on-year increase of 19.37%; net income attributable to shareholders of the listed company was 11.3147 million yuan, a year-on-year decrease of 46.91%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 10.7105 million yuan, a year-on-year decrease of 36.75%; basic earnings per share was 0.1 yuan.
Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) CEO Da Lin Ye, the Company's Largest Shareholder Sees 17% Reduction in Holdings Value
Tailin (300813.SZ): Wholly-owned subsidiaries have obtained a total of 8 patent certificates.
Gelonghui, September 10th, Tailin Biotech (300813.SZ) announced that its wholly-owned subsidiaries Zhejiang Tailin Analytical Instrument Co., Ltd. (referred to as "Tailin Analytical Instrument"), Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science"), and Zhejiang Tailin Medical Engineering Co., Ltd. (referred to as "Tailin Medical Engineering") have recently obtained 8 patent certificates (including 2 invention patents). The specific situation is as follows:
Optimistic Investors Push Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) Shares Up 28% But Growth Is Lacking
No Data
